[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 4 sources · 6 days · First seen · Last updated

Mebufotenin nasal spray depression research

Overview

Research involving participants from Australia, the United States, and Europe suggests that a synthetic nasal spray containing mebufotenin, or 5-MeO-DMT, may offer long-lasting relief for treatment-resistant depression. Clinical trial results published in the Journal of the American Medical Association indicate that a single dose can significantly reduce depressive symptoms for at least eight weeks.

Unlike traditional psychedelic treatments that require supervised sessions lasting several hours, this nasal spray is fast-acting, with most patients cleared for release less than two hours after administration. Biotech firm Atai Life Sciences developed this synthetic version to provide therapeutic benefits without the need to harvest secretions from the Sonoran desert toad, a move intended to protect amphibian populations.

Entities

Journal of the American Medical Association · Sonoran desert toad · Atai Life Sciences

Timeline

  1. [HEALTH] 2 sources
    Atai Life Sciences develops psychedelic nasal spray for depression

    A clinical trial published in JAMA suggests a new synthetic mebufotenin nasal spray may treat treatment-resistant depression without the need for long-duration psychedelic experiences.

  2. [HEALTH] 2 sources
    Mebufotenin nasal spray shows promise for treatment-resistant depression

    A study on mebufotenin (5-MeO-DMT) nasal spray indicates that a single dose can significantly reduce depression symptoms for weeks in patients resistant to standard antidepressants.

Sources

brainmatters.nl · popsci.com · scientias.nl · wdctv.news